Bioventix PLC (BVXP) · 2026-10-26
Results for the year ended 30 June 2026
Bioventix PLC said FY2026 revenue and profit after tax were slightly ahead of market expectations, but reported revenue fell to £13.0m from £13.1m as legacy products faced pressure. A terminated progesterone-antibody contract will remove about £400,000 of annual revenue from future periods.